Vaccine profile of PPV23: Beijing Minhai Biotech 23-valent pneumococcal vaccine

References

• 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec. 2008;83(42):373–384.
   Google Scholar
• Boulton ML, Ravi NS, Sun X, et al. Trends in childhood pneumococcal vaccine coverage in Shanghai, China, 2005–2011: a retrospective cohort study. BMC Public Health. 2015;16(1):1–7.
   Web of Science ®Google Scholar
• Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA. 1993;270(15):1826–1831.
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893–902.
   PubMed Web of Science ®Google Scholar
• Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ. 2004;82(5):346–353.
   PubMed Web of Science ®Google Scholar
• Daniels CC, Rogers PD, Shelton CM. A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens. J Pediatr Pharmacol Ther. 2016;21(1):27–35.
   PubMedGoogle Scholar
• Moberley SA, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2008;23(1):CD000422.
   PubMed Web of Science ®Google Scholar
• Huss A, Scott P, Stuck AE, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ. 2009;180(1):48–58.
   PubMed Web of Science ®Google Scholar
• Conaty S, Watson L, Dinnes J, et al. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine. 2004;22(23–24):3214–3224.
   PubMed Web of Science ®Google Scholar
• Zhogolev SD, Ogarkov PI, Mel’nichenko PI. The prophylaxis of nonhospital pneumonia using 23-valent pneumococcus vaccine in the military collectives. Voen Med Zh. 2004;325(12):35–43, 96.
   PubMedGoogle Scholar
• Mangtani P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis. 2003;3(2):71–78.
   PubMed Web of Science ®Google Scholar
• Mykietiuk A, Carratala J, Dominguez A, et al. Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with community-acquired pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis. 2006;25(7):457–462.
   PubMed Web of Science ®Google Scholar
• Fisman DN, Abrutyn E, Spaude KA, et al. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis. 2006;42(8):1093–1101.
   PubMed Web of Science ®Google Scholar
• Johnstone J, Marrie TJ, Eurich DT, et al. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med. 2007;167(18):1938–1943.
   PubMedGoogle Scholar
• Penaranda M, Falco V, Payeras A, et al. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study. Clin Infect Dis. 2007;45(7):e82–e87.
   PubMed Web of Science ®Google Scholar
• Breiman RF, Keller DW, Phelan MA, et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med. 2000;160(17):2633–2638.
   PubMedGoogle Scholar
• Feikin DR, Feldman C, Schuchat A, et al. Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis. 2004;4(7):445–455.
   PubMed Web of Science ®Google Scholar
• Ohtola JA, Saul-McBeth JL, Iyer AS, et al. Quantitative and functional antibody responses to the 13-valent conjugate and/or 23-valent purified polysaccharide vaccine in aging HIV-infected adults. J AIDS Clin Res. 2016;7(3):556.
   PubMedGoogle Scholar
• Rodriguez-Barradas MC, Serpa JA, Munjal I, et al. Quantitative and qualitative antibody responses to immunization with the pneumococcal polysaccharide vaccine in HIV-infected patients after initiation of antiretroviral treatment: results from a randomized clinical trial. J Infect Dis. 2015;211(11):1703–1711.
   PubMed Web of Science ®Google Scholar
• Lee KY, Tsai MS, Kuo KC, et al. Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy. Hum Vaccin Immunother. 2014;10(12):3700–3710.
   PubMed Web of Science ®Google Scholar
• Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA. 2001;285(13):1729–1735.
   PubMed Web of Science ®Google Scholar
• Pneumococcal vaccines: WHO position paper - 2012. Wkly Epidemiol Rec. 2000;75(20):161–169.
   Google Scholar
• McFetridge R, Meulen AS, Folkerth SD, et al. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults. Vaccine. 2015;33(24):2793–2799.
   PubMed Web of Science ®Google Scholar
• Evers SM, Ament AJ, Colombo GL, et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol. 2007;26(8):531–540.
   Google Scholar
• Musher DM. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? Clin Infect Dis Off Publ Infect Dis Soc America. 2011;52(5):633–640.
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11(10):760–768.
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Maes C, De Boever F, et al. Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study. Vaccine. 2014;32(50):6838–6846.
   PubMed Web of Science ®Google Scholar
• Prymula R, Pazdiora P, Traskine M, et al. Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trial. Vaccine. 2014;32(25):3025–3034.
   PubMed Web of Science ®Google Scholar
• Brooks WA, Chang LJ, Sheng X, et al. Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: A phase I randomized controlled study. Vaccine. 2015;33(36):4610–4617.
   PubMed Web of Science ®Google Scholar
• Leal-Esteban LC, Rojas JL, Jaimes AL, et al. [An immunoenzymatic test for IgG antibody levels against 10 serotypes of Streptococcus pneumoniae]. Biomed. 2012;32(1):37–39.
   Google Scholar
• Wernette CM, Frasch CE, Madore D, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol. 2003;10(4):514–519.
   PubMedGoogle Scholar
• Song JY, Moseley MA, Burton RL, et al. Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother. 2013;19(3):412–425.
   PubMed Web of Science ®Google Scholar
• Li G, Liang Q, Shi J, et al. Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in 2 to 70 year old healthy people in China: A phase III double blind, randomized clinical trial. Hum Vaccin Immunother. 2015;11(3):699–703.
   PubMed Web of Science ®Google Scholar
• Ciprero K, Zykov KA, Briko NI, et al. Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects. Hum Vaccin Immunother. 2016. doi:10.1080/21645515.2016.1165373. [Epub ahead of print]
   Web of Science ®Google Scholar
• Kong Y, Zhang W, Jiang Z, et al. Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in Chinese healthy population aged >2 years: a randomized, double-blinded, active control, phase III trial. Hum Vaccin Immunother. 2015;11(10):2425–2433.
   PubMed Web of Science ®Google Scholar
• Miller ER, Moro PL, Cano M, et al. Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013. Vaccine. 2016;34(25):2841–2846.
   PubMed Web of Science ®Google Scholar
• Pneumococcal polysaccharide vaccine. Recommendation of the Immunization Practices Advisory Committee. Ann Intern Med. 1982;96(2):203–205.
   PubMed Web of Science ®Google Scholar
• Che D, Zhou H, He J, et al. Modeling the impact of the 7-valent pneumococcal conjugate vaccine in Chinese infants: an economic analysis of a compulsory vaccination. BMC Health Serv Res. 2014;14(1):56–56.
   PubMed Web of Science ®Google Scholar
• Hou Z, Chang J, Yue D, et al. Determinants of willingness to pay for self-paid vaccines in China. Vaccine. 2014;32(35):4471–4477.
   PubMed Web of Science ®Google Scholar
• Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325(21):1453–1460.
   PubMed Web of Science ®Google Scholar
• Lombardi F, Belmonti S, Fabbiani M, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: a pilot, prospective controlled study. PLoS One. 2016;11(6):e0156523.
   Web of Science ®Google Scholar
• Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis Off Publ Infect Dis Soc America. 2014;58(3):44–100.
   PubMed Web of Science ®Google Scholar
• Blommaert A, Bilcke J, Willem L, et al. The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: an exploration of influential factors for Belgium. Vaccine. 2016;34(18):2106–2112.
   PubMed Web of Science ®Google Scholar
• Konradsen HB, Sorensen UB, Henrichsen J. A modified enzyme-linked immunosorbent assay for measuring type-specific anti-pneumococcal capsular polysaccharide antibodies. J Immunol Methods. 1993;164(1):13–20.
   PubMed Web of Science ®Google Scholar
• Henckaerts I, Goldblatt D, Ashton L, et al. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol. 2006;13(3):356–360.
   PubMed Web of Science ®Google Scholar
• Ciprero KL, Marchese RD, Richard P, et al. Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes. Hum Vaccin Immunother. 2016. doi:10.1080/21645515.2016.1156270. [Epub ahead of print]
   Web of Science ®Google Scholar
• Ahn JG, Kim HW, Choi HJ, et al. Functional immune responses to twelve serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults. Vaccine. 2015;33(38):4770–4775.
   PubMed Web of Science ®Google Scholar
• Shiramoto M, Hanada R, Juergens C, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults. Hum Vaccin Immunother. 2015;11(9):2198–2206.
   PubMed Web of Science ®Google Scholar